Grant awarded to CHOP and collaborating institutions will fund research into identifying and treating slowly progressive neuroblastoma, which currently lacks treatment options.

The award was presented to the St. Baldrick’s Foundation-Stand Up 2 Cancer Pediatric Cancer Dream Team, co-led by CHOP, at the annual AACR conference.

Established in 2015, the Evan Lindberg Neuroblastoma Research Scholars Program supports exceptional early-career scientists at CHOP who are dedicated to finding a cure for neuroblastoma.

CHOP researchers will receive funds to discover a new drug that targets MYCN, a transcription factor involved in some pediatric cancers.

Dr. Shannon Maude, an attending physician in the Cancer Center at CHOP, provided expert insight on the unique challenges facing CAR T-cell therapy for pediatric indications in an article published in Healio’s February issue of Cell Therapy Next.

The National Comprehensive Cancer Network (NCCN) recently published its first-ever treatment guidelines for Wilms' tumor.

A multispecialty collaboration of oncology, urology, and radiology saved the patient from undergoing two rounds of anesthesia.

The FDA has approved a treatment that targets ALK mutations in relapsed, refractory ALK-positive anaplastic large cell lymphoma.

CHOP researchers found the elevated biomarker in all children who tested positive for SARS-CoV-2, whether they were symptomatic for COVID-19 or not.

The CHOP physician-researcher’s investigation into cause of and treatment for neuroblastoma has been supported by Conquer Cancer grants.